Update on Phase I trial of Vaccine BIL06v

Biosceptres’ Phase I clinical trial for peptide vaccine BIL06v has now completed enrolment of the first cohort of ten patients at the first dose, and all enrolled patients have received treatment. The trial was initiated in August and, subject to a scheduled safety review this week, it is expected that recruitment of the second cohort will begin before end of November.

Gavin Currie CEO said “It is pleasing that we have been able to exceed forecast recruitment rates through the two sites we have initiated, the Sydney Adventist Hospital Wahroonga, and Sydney Southwest Private Hospital. With a third site ready to initiate if recruitment is an issue going forward, we are confident the trial will continue to progress smoothly. Assuming a similar rate of recruitment for the second cohort the Phase I trial remains on track to be completed around Q3 2019.”